Regulation of RAF protein kinases in ERK signalling

Nature Reviews Molecular Cell Biology

Volumn 16, Issue 5, 2015, Pages 281-298

  Lavoie, Hugo ^a   Therrien, Marc ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KINASE SUPPRESSOR OF RAS; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PHOSPHOTRANSFERASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BINDING SITE; CELL DIFFERENTIATION; CELL GROWTH; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; IN VITRO STUDY; MUTATION; NEGATIVE FEEDBACK; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; MULTIPLE MALFORMATION SYNDROME;

ABNORMALITIES, MULTIPLE; ANIMALS; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASMS; RAF KINASES;

EID: 84929077789     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm3979     Document Type: Review

References (248)

1. Matallanas, D. et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2, 232-260 (2011).
2. Rapp, U. R. et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl Acad. Sci. USA 80, 4218-4222 (1983).
3. Rapp, U. R. & Todaro, C. Generation of new mouse sarcoma viruses in cell culture. Science 201, 821-824 (1978).
4. Jansen, H. W. et al. Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611. Nature 307, 281-284 (1984).
5. Kan, N. C., Flordellis, C. S., Mark, G. E., Duesberg, P. H. & Papas, T. S. A common onc gene sequence transduced by avian carcinoma virus MH2 and by murine sarcoma virus 3611. Science 223, 813-816 (1984).
6. Sutrave, P. et al. Nucleotide sequence of avian retroviral oncogene v-mil: homologue of murine retroviral oncogene v-raf. Nature 309, 85-88 (1984).
7. Moelling, K., Heimann, B., Beimling, P., Rapp, U. R. & Sander, T. Serine-and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 312, 558-561 (1984).
8. Bonner, T. et al. The human homologs of the raf (mil) oncogene are located on human chromosomes 3 and 4. Science 223, 71-74 (1984).
9. Ishikawa, F et al. Activated c-raf gene in a rat hepatocellular carcinoma induced by 2-amino-3-methylimidazo[4, 5-f]quinoline. Biochem. Biophys. Res. Commun. 132, 186-192 (1985).
10. Kozak, C, Gunnell, M. A. & Rapp, U. R. A new oncogene, c-raf, is located on mouse chromosome 6. J. Virol. 49, 297-299 (1984).
11. Bonner, T. I. et al. Structure and biological activity of human homologs of the raf/mil oncogene. Mol. Cell. Biol. 5, 1400-1407 (1985).
12. Fukui, M., Yamamoto, T., Kawai, S., Mitsunobu, F. & Toyoshima, K. Molecular cloning and characterization of an activated human c-raf-1 gene. Mol. Cell. Biol. 7, 1776-1781 (1987).
13. Ishikawa, F., Takaku, F., Hayashi, K., Nagao, M. & Sugimura, T. Activation of rat c-raf during transfection of hepatocellular carcinoma DNA. Proc. Natl Acad. Sci. USA 83, 3209-3212 (1986).
14. Molders, H. et al. Integration of transfected LTR sequences into the c-raf proto-oncogene: activation by promoter insertion. EMBO J. 4, 693-698 (1985).
15. Stanton, V. P. Jr & Cooper, G. M. Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences. Mol. Cell. Biol. 7, 1171-1179 (1987).
16. Schultz, A. M., Copeland, T., Oroszlan, S. & Rapp, U. R. Identification and characterization of c-raf phosphoproteins in transformed murine cells. Oncogene 2, 187-193 (1988).
17. Stanton, V. P. Jr., Nichols, D. W., Laudano, A. P. & Cooper, G. M. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol. Cell. Biol. 9, 639-647 (1989).
18. Ishikawa, F. et al. Identification of a transforming activity suppressing sequence in the c-raf oncogene. Oncogene 3, 653-658 (1988).
19. Heidecker, G. et al. Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol. Cell. Biol. 10, 2503-2512 (1990).
20. Bruder, J. T., Heidecker, G. & Rapp, U. R. Serum-, TPA-, and Ras-induced expression from Ap-1/Ets-driven promoters requires Raf-1 kinase. Genes Dev. 6, 545-556 (1992).
21. Huebner, K. et al. Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. Proc. Natl Acad. Sci. USA 83, 3934-3938 (1986).
22. Huleihel, M. et al. Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol. Cell. Biol. 6, 2655-2662 (1986).
23. Mark, G. E., Seeley, T. W., Shows, T. B. & Mountz, J. D. pks, a raf-related sequence in humans. Proc. Natl Acad. Sci. USA 83, 6312-6316 (1986).
24. Ishikawa, F., Takaku, F., Nagao, M. & Sugimura, T The complete primary structure of the rat A-raf cDNA coding region: conservation of the putative regulatory regions present in rat c-raf. Oncogene Res. 1, 243-253 (1987).
25. Ikawa, S. et al. B-raf, a new member of the raf family, is activated by DNA rearrangement Mol. Cell. Biol. 8, 2651-2654 (1988).
26. Beck, T W., Huleihel, M., Gunnell, M., Bonner, T. I. & Rapp, U. R. The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus. Nucleic Acids Res. 15, 595-609 (1987).
27. Chuang, E. et al. Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues. Mol. Cell. Biol. 14, 5318-5325 (1994).
28. Smith, M. R., DeGudicibus, S. J. & Stacey, D. W Requirement for c-ras proteins during viral oncogene transformation. Nature 320, 540-543 (1986).
29. Mark, G. E., MacIntyre, R. J., Digan, M. E., Ambrosio, L. & Perrimon, N. Drosophila melanogaster homologs of the raf oncogene. Mol. Cell. Biol. 7, 2134-2140 (1987).
30. Nishida, Y. et al. Proliferation of both somatic and germ cells is affected in the Drosophila mutants of raf proto-oncogene. EMBO J. 7, 775-781 (1988).
31. Ambrosio, L, Mahowald, A. P. & Perrimon, N. Requirement of the Drosophila raf homologue for torso function. Nature 342, 288-291 (1989).
32. Han, M., Golden, A., Han, Y & Sternberg, P. W C. elegans lin-45 raf gene participates in let-60 ras-stimulated vulval differentiation. Nature 363, 133-140 (1993).
33. Ray, L. B. & Sturgill, T. W. Rapid stimulation by insulin of a serine/threonine kinase in 3T3-L1 adipocytes that phosphorylates microtubule-associated protein 2 in vitro. Proc. Natl Acad. Sci. USA 84, 1502-1506 (1987).
34. Boulton, T. G. et al. An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science 249, 64-67 (1990).
35. Rossomando, A. J., Payne, D. M., Weber, M. J. & Sturgill, T. W. Evidence that pp42, a major tyrosine kinase target protein, is a mitogen-activated serine/threonine protein kinase. Proc. Natl Acad. Sci. USA 86, 6940-6943 (1989).
36. Boulton, T. G. et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65, 663-675 (1991).
37. Crews, C. M. & Erikson, R. L. Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product. Proc. Natl Acad. Sci. USA 89, 8205-8209 (1992).
38. Yoon, S. & Seger, R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24, 21-44 (2006).
39. Kyriakis, J. M. et al. Raf-1 activates MAP kinase-kinase. Nature 358, 417-421 (1992).
40. Kolch, W., Heidecker, G., Lloyd, P. & Rapp, U. R. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349, 426-428 (1991).
41. Leevers, S. J. & Marshall, C. J. Activation of extracellular signal-regulated kinase, ERK2, by p2 1ras oncoprotein. EMBO J. 11, 569-574 (1992).
42. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nature Rev. Cancer 3, 459-465 (2003).
43. Zhang, X. F. et al. Normal and oncogenic p2 1ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364, 308-313 (1993).
44. Van Aelst, L, Barr, M., Marcus, S., Polverino, A. & Wigler, M. Complex formation between RAS and RAF and other protein kinases. Proc. Natl Acad. Sci. USA 90, 6213-6217 (1993).
45. Vojtek, A. B., Hollenberg, S. M. & Cooper, J. A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74, 205-214 (1993).
46. Moodie, S. A., Willumsen, B. M., Weber, M. J. & Wolfman, A. Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260, 1658-1661 (1993).
47. Dent, P., Reardon, D. B., Morrison, D. K. & Sturgill, T. W Regulation of Raf-1 and Raf-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro. Mol. Cell. Biol. 15, 4125-4135 (1995).
48. Fantl, W J. et al. Activation of Raf-1 by 14-3-3 proteins. Nature 371, 612-614 (1994).
49. Freed, E., Symons, M., Macdonald, S. G., McCormick, F & Ruggieri, R. Binding of 14-3-3 proteins to the protein kinase Raf and effects on its activation. Science 265, 1713-1716 (1994).
50. Fu, H. et al. Interaction of the protein kinase Raf-1 with 14-3-3 proteins. Science 266, 126-129 (1994).
51. Irie, K. et al. Stimulatory effects of yeast and mammalian 14-3-3 proteins on the Raf protein kinase. Science 265, 1716-1719 (1994).
52. Stancato, L. F et al. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J. Biol. Chem. 268, 21711-21716 (1993).
53. Kornfeld, K., Hom, D. B. & Horvitz, H. R. The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans. Cell 83, 903-913 (1995).
54. Sundaram, M. & Han, M. The C. elegans ksr-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. Cell 83, 889-901 (1995).
55. Therrien, M. et al. KSR, a novel protein kinase required for RAS signal transduction. Cell 83, 879-888 (1995).
56. Channavajhala, P. L. et al. Identification of a novel human kinase supporter of Ras (hKSR-2) that functions as a negative regulator of Cot (Tpl2) signaling. J. Biol. Chem. 278, 47089-47097 (2003).
57. Koveal, D. et al. A CC-SAM, for coiled coil-sterile a motif, domain targets the scaffold KSR-1 to specific sites in the plasma membrane. Sci. Signal. 5, ra94 (2012).
58. Zhou, M., Horita, D. A., Waugh, D. S., Byrd, R. A. & Morrison, D. K. Solution structure and functional analysis of the cysteine-rich C1 domain of kinase suppressor of Ras (KSR). J. Mol. Biol. 315, 435-446 (2002).
59. Jacobs, D., Glossip, D., Xing, H., Muslin, A. J. & Kornfeld, K. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. Genes Dev. 13, 163-175 (1999).
60. Rajakulendran, T, Sahmi, M., Lefrancois, M., Sicheri, F & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
61. Nguyen, A. et al. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol. Cell. Biol. 22, 3035-3045 (2002).
62. Roy, F., Laberge, G., Douziech, M., Ferland-McCollough, D. & Therrien, M. KSR is a scaffold required for activation of the ERK/MAPK module. Genes Dev. 16, 427-438 (2002).
63. Stewart, S. et al. Kinase suppressor of Ras forms a multiprotein signaling complex and modulates MEK localization. Mol. Cell. Biol. 19, 5523-5534 (1999).
64. Brennan, D. F. et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472, 366-369 (2011).
65. Goettel, J. A. et al. KSR1 is a functional protein kinase capable of serine autophosphorylation and direct phosphorylation of MEK1. Exp. Cell Res. 317, 452-463 (2011).
66. Hu, J. et al. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF. Proc. Natl Acad. Sci. USA 108, 6067-6072 (2011).
67. Zhang, Y. et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 89, 63-72 (1997).
68. Michaud, N. R. et al. KSR stimulates Raf-1 activity in a kinase-independent manner. Proc. Natl Acad. Sci. USA 94, 12792-12796 (1997).
69. Chong, H. & Guan, K. L. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J. Biol. Chem. 278, 36269-36276 (2003).
70. Cutler, R. E. Jr., Stephens, R. M., Saracino, M. R. & Morrison, D. K. Autoregulation of the Raf-1 serine/threonine kinase. Proc. Natl Acad. Sci. USA 95, 9214-9219 (1998).
71. Tran, N. H. & Frost, J. A. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J. Biol. Chem. 278, 11221-11226 (2003).
72. Tran, N. H., Wu, X. & Frost, J. A. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J. Biol. Chem. 280, 16244-16253 (2005).
73. Cook, S. J. & McCormick, F. Inhibition by cAMP of Ras-dependent activation of Raf. Science 262, 1069-1072 (1993).
74. Wu, J. et al. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′, 5′-monophosphate. Science 262, 1065-1069 (1993).
75. Dhillon, A. S. et al. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol. Cell. Biol. 22, 3237-3246 (2002).
76. Zimmermann, S. & Moelling, K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286, 1741-1744 (1999).
77. Rommel, C. et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286, 1738-1741 (1999).
78. Romano, D. et al. Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling. Nature Cell Biol. 16, 673-684 (2014).
79. Morrison, D. K., Heidecker, G., Rapp, U. R. & Copeland, T. D. Identification of the major phosphorylation sites of the Raf-1 kinase. J. Biol. Chem. 268, 17309-17316 (1993).
80. Dhillon, A. S., Meikle, S., Yazici, Z., Eulitz, M. & Kolch, W. Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J. 21, 64-71 (2002).
81. Light, Y., Paterson, H. & Marais, R. 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol. Cell. Biol. 22, 4984-4996 (2002).
82. Michaud, N. R., Fabian, J. R., Mathes, K. D. & Morrison, D. K. 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3-and Ras-independent manner. Mol. Cell. Biol. 15, 3390-3397 (1995).
83. Rommel, C. et al. Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1. Oncogene 12, 609-619 (1996).
84. Muslin, A. J., Tanner, J. W., Allen, P. M. & Shaw, A. S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889-897 (1996).
85. Tzivion, G., Luo, Z. & Avruch, J. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394, 88-92 (1998).
86. Dumaz, N. & Marais, R. Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. J. Biol. Chem. 278, 29819-29823 (2003).
87. Molzan, M. & Ottmann, C. Synergistic binding of the phosphorylated S233-and S259-binding sites of C-RAF to one 14-3-3ζ dimer. J. Mol. Biol. 423, 486-495 (2012).
88. Ahearn, I. M., Haigis, K., Bar-Sagi, D. & Philips, M. R. Regulating the regulator: post-translational modification of RAS. Nature Rev. Mol. Cell Biol. 13, 39-51 (2012).
89. Nassar, N. et al. The 2.2Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 375, 554-560 (1995).
90. Huang, L., Hofer, F., Martin, G. S. & Kim, S. H. Structural basis for the interaction of Ras with RalGDS. Nature Struct. Biol. 5, 422-426 (1998).
91. Pacold, M. E. et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ. Cell 103, 931-943 (2000).
92. Fabian, J. R., Vojtek, A. B., Cooper, J. A. & Morrison, D. K. A single amino acid change in Raf-1 inhibits Ras binding and alters Raf-1 function. Proc. Natl Acad. Sci. USA 91, 5982-5986 (1994).
93. Baljuls, A. et al. The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF. J. Biol. Chem. 287, 23128-23140 (2012).
94. Im, E. et al. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene 21, 6356-6365 (2002).
95. Vossler, M. R. et al. cAMP activates MAP kinase and Elk-1 through a B-Raf-and Rap1-dependent pathway. Cell 89, 73-82 (1997).
96. Rodriguez-Viciana, P., Sabatier, C. & McCormick, F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24, 4943-4954 (2004).
97. Leonard, T. A. & Hurley, J. H. Regulation of protein kinases by lipids. Curr. Opin. Struct. Biol. 21, 785-791 (2011).
98. Ghosh, S. et al. The cysteine-rich region of raf-1 kinase contains zinc, translocates to liposomes, and is adjacent to a segment that binds GTP-ras. J. Biol. Chem. 269, 10000-10007 (1994).
99. Ghosh, S., Strum, J. C., Sciorra, V. A., Daniel, L. & Bell, R. M. Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. J. Biol. Chem. 271, 8472-8480 (1996).
100. Roy, S., Lane, A., Yan, J., McPherson, R. & Hancock, J. F. Activity of plasma membrane-recruited Raf-1 is regulated by Ras via the Raf zinc finger. J. Biol. Chem. 272, 20139-20145 (1997).
101. Bondeva, T., Balla, A., Varnai, P. & Balla, T. Structural determinants of Ras-Raf interaction analyzed in live cells. Mol. Biol. Cell 13, 2323-2333 (2002).
102. Fischer, A. et al. B-and C-RAF display essential differences in their binding to Ras: the isotype-specific N terminus of B-RAF facilitates Ras binding. J. Biol. Chem. 282, 26503-26516 (2007).
103. Luo, Z., Diaz, B., Marshall, M. S. & Avruch, J. An intact Raf zinc finger is required for optimal binding to processed Ras and for ras-dependent Raf activation in situ. Mol. Cell. Biol. 17, 46-53 (1997).
104. Williams, J. G. et al. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. J. Biol. Chem. 275, 22172-22179 (2000).
105. Winkler, D. G. et al. Identification of residues in the cysteine-rich domain of Raf-1 that control Ras binding and Raf-1 activity. J. Biol. Chem. 273, 21578-21584 (1998).
106. Thapar, R., Williams, J. G. & Campbell, S. L. NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. J. Mol. Biol. 343, 1391-1408 (2004).
107. Abraham, D. et al. Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J. Biol. Chem. 275, 22300-22304 (2000).
108. Jaumot, M. & Hancock, J. F. Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene 20, 3949-3958 (2001).
109. Ory, S., Zhou, M., Conrads, T. P., Veenstra, T. D. & Morrison, D. K. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr. Biol. 13, 1356-1364 (2003).
110. Farrar, M. A., Alberol-Ila, J. & Perlmutter, R. M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature 383, 178-181 (1996).
111. Luo, Z. et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383, 181-185 (1996).
112. Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active RAS induces heterodimerization of CRAF and BRAF. Cancer Res. 61, 3595-3598 (2001).
113. Rushworth, L. K., Hindley, A. D., O'Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 26, 2262-2272 (2006).
114. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
115. Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969 (2005).
116. Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
117. Douziech, M., Sahmi, M., Laberge, G. & Therrien, M. A. KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in Drosophila. Genes Dev. 20, 807-819 (2006).
118. Taylor, S. S. & Kornev, A. P. Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem. Sci. 36, 65-77 (2011).
119. Kornev, A. P., Haste, N. M., Taylor, S. S. & Eyck, L. F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl Acad. Sci. USA 103, 17783-17788 (2006).
120. Shaw, A. S., Kornev, A. P., Hu, J., Ahuja, L. G. & Taylor, S. S. Kinases and pseudokinases: lessons from RAF. Mol. Cell. Biol. 34, 1538-1546 (2014).
121. Lavoie, H. et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nature Chem. Biol. 9, 428-436 (2013).
122. Thevakumaran, N. et al. Crystal structure of a BRAF kinase domain monomer explains basis for allosteric regulation. Nature Struct. Mol. Biol. 22, 37-43 (2015).
123. Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
124. Roring, M. et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 31, 2629-2647 (2012).
125. Freeman, A. K., Ritt, D. A. & Morrison, D. K. Effects of raf dimerization and its inhibition on normal and disease-associated raf signaling. Mol. Cell 49, 751-758 (2013).
126. Plowman, S. J., Muncke, C., Parton, R. G. & Hancock, J. F. H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton. Proc. Natl Acad. Sci. USA 102, 15500-15505 (2005).
127. Tian, T. et al. Plasma membrane nanoswitches generate high-fidelity Ras signal transduction. Nature Cell Biol. 9, 905-914 (2007).
128. Dementiev, A. K-Ras4B lipoprotein synthesis: biochemical characterization, functional properties, and dimer formation. Protein Expr Purif. 84, 86-93 (2012).
129. Guldenhaupt, J. et al. N-Ras forms dimers at POPC membranes. Biophys. J. 103, 1585-1593 (2012).
130. Lin, W. C. et al. H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc. Natl Acad. Sci. USA 111, 2996-3001 (2014).
131. Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
132. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
133. Cho, K. J. et al. Raf inhibitors target ras spatiotemporal dynamics. Curr. Biol. 22, 945-955 (2012).
134. Ghosh, S., Moore, S., Bell, R. M. & Dush, M. Functional analysis of a phosphatidic acid binding domain in human Raf-1 kinase: mutations in the phosphatidate binding domain lead to tail and trunk abnormalities in developing zebrafish embryos. J. Biol. Chem. 278, 45690-45696 (2003).
135. Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 40, D261-D270 (2012).
136. Marais, R., Light, Y., Paterson, H. F. & Marshall, C. J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14, 3136-3145 (1995).
137. Diaz, B. et al. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol. Cell. Biol. 17, 4509-4516 (1997).
138. Marais, R., Light, Y., Paterson, H. F., Mason, C. S. & Marshall, C. J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 272, 4378-4383 (1997).
139. Mason, C. S. et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18, 2137-2148 (1999).
140. v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase. Proc. Natl Acad. Sci. USA 89, 2922-2926 (1992).
141. Thompson, P. A., Ledbetter, J. A., Rapp, U. R. & Bolen, J. B. The Raf-1 serine-threonine kinase is a substrate for the p56lck protein tyrosine kinase in human T cells. Cell Growth Differ. 2, 609-617 (1991).
142. Fabian, J. R., Daar, I. O. & Morrison, D. K. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell. Biol. 13, 7170-7179 (1993).
143. Cleghon, V. & Morrison, D. K. Raf-1 interacts with Fyn and Src in a non-phosphotyrosine-dependent manner. J. Biol. Chem. 269, 17749-17755 (1994).
144. Chaudhary, A. et al. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr. Biol. 10, 551-554 (2000).
145. King, A. J. et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396, 180-183 (1998).
146. Sun, H., King, A. J., Diaz, H. B. & Marshall, M. S. Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Curr. Biol. 10, 281-284 (2000).
147. Chiloeches, A., Mason, C. S. & Marais, R. S338 phosphorylation of Raf-1 is independent of phosphatidylinositol 3-kinase and Pak3. Mol. Cell. Biol. 21, 2423-2434 (2001).
148. Ritt, D. A. et al. CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation. Curr. Biol. 17, 179-184 (2007).
149. Hu, J. et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154, 1036-1046 (2013).
150. Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149 (2006).
151. Baljuls, A. et al. Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites. J. Biol. Chem. 283, 27239-27254 (2008).
152. Zhang, B. H. & Guan, K. L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19, 5429-5439 (2000).
153. Chong, H., Lee, J. & Guan, K. L. Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J. 20, 3716-3727 (2001).
154. Dhillon, A. S. et al. The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell Signal 21, 1645-1651 (2009).
155. Mischak, H. et al. Negative regulation of Raf-1 by phosphorylation of serine 621. Mol. Cell. Biol. 16, 5409-5418 (1996).
156. Shen, C. H. et al. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol. Cell 52, 161-172 (2013).
157. Noble, C. et al. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol. Cell 31, 862-872 (2008).
158. Sprenkle, A. B., Davies, S. P., Carling, D., Hardie, D. G. & Sturgill, T. W. Identification of Raf-1 Ser621 kinase activity from NIH 3T3 cells as AMP-activated protein kinase. FEBS Lett. 403, 254-258 (1997).
159. Yu, W., Fantl, W. J., Harrowe, G. & Williams, L. T. Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK. Curr. Biol. 8, 56-64 (1998).
160. Therrien, M., Wong, A. M. & Rubin, G. M. CNK, a RAF-binding multidomain protein required for RAS signaling. Cell 95, 343-353 (1998).
161. Sieburth, D. S., Sun, Q. & Han, M. SUR-8, a conserved Ras-binding protein with leucine-rich repeats, positively regulates Ras-mediated signaling in C. elegans. Cell 94, 119-130 (1998).
162. Luttrell, L. M. et al. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc. Natl Acad. Sci. USA 98, 2449-2454 (2001).
163. Ishibe, S., Joly, D., Zhu, X. & Cantley, L. G. Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. Mol. Cell 12, 1275-1285 (2003).
164. Vomastek, T. et al. Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists. Proc. Natl Acad. Sci. USA 101, 6981-6986 (2004).
165. Smith, F. D. et al. AKAP-Lbc enhances cyclic AMP control of the ERK1/2 cascade. Nature Cell Biol. 12, 1242-1249 (2010).
166. Ren, J. G., Li, Z. & Sacks, D. B. IQGAP1 modulates activation of B-Raf. Proc. Natl Acad. Sci. USA 104, 10465-10469 (2007).
167. Kolch, W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nature Rev. Mol. Cell Biol. 6, 827-837 (2005).
168. Good, M., Tang, G., Singleton, J., Remenyi, A. & Lim, W. A. The Ste5 scaffold directs mating signaling by catalytically unlocking the Fus3 MAP kinase for activation. Cell 136, 1085-1097 (2009).
169. Kortum, R. L. & Lewis, R. E. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol. Cell. Biol. 24, 4407-4416 (2004).
170. V12-induced and replicative senescence. Mol. Cell. Biol. 26, 2202-2214 (2006).
171. McKay, M. M., Ritt, D. A. & Morrison, D. K. Signaling dynamics of the KSR1 scaffold complex. Proc. Natl Acad. Sci. USA 106, 11022-11027 (2009).
172. Muller, J., Ory, S., Copeland, T., Piwnica-Worms, H. & Morrison, D. K. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol. Cell 8, 983-993 (2001).
173. Cacace, A. M. et al. Identification of constitutive and ras-inducible phosphorylation sites of KSR: implications for 14-3-3 binding, mitogen-activated protein kinase binding, and KSR overexpression. Mol. Cell. Biol. 19, 229-240 (1999).
174. McKay, M. M., Ritt, D. A. & Morrison, D. K. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr. Biol. 21, 563-568 (2011).
175. Dougherty, M. K. et al. KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. Mol. Cell 34, 652-662 (2009).
176. Haling, J. R. et al. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell 26, 402-413 (2014).
177. Dar, A. C, Dever, T. E. & Sicheri, F. Higher-order substrate recognition of eIF2a by the RNA-dependent protein kinase PKR. Cell 122, 887-900 (2005).
178. von Kriegsheim, A., Pitt, A., Grindlay, G. J., Kolch, W & Dhillon, A. S. Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5. Nature Cell Biol. 8, 1011-1016 (2006).
179. Dougherty, M. K. et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215-224 (2005).
180. Ritt, D. A., Monson, D. M., Specht, S. I. & Morrison, D. K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 30, 806-819 (2010).
181. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
182. Fukushima, T. et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22, 6455-6457 (2003).
183. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 39, D945-D950 (2011).
184. Rodriguez-Viciana, P. et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311, 1287-1290 (2006).
185. Niihori, T. et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nature Genet. 38, 294-296 (2006).
186. Pandit, B. et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nature Genet. 39, 1007-1012 (2007).
187. Razzaque, M. A. et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nature Genet. 39, 1013-1017 (2007).
188. Rauen, K. A. The RASopathies. Annu. Rev. Genom. Hum. Genet. 14, 355-369 (2013).
189. Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673-8677 (2008).
190. Cin, H. et al. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathol. 121, 763-774 (2011).
191. Palanisamy, N. et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Med. 16, 793-798 (2010).
192. Ciampi, R. et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 115, 94-101 (2005).
193. Stransky, N., Cerami, E., Schalm, S., Kim, J. L. & Lengauer, C. The landscape of kinase fusions in cancer. Nature Commun. 5, 4846 (2014).
194. Molzan, M. et al. Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol. Cell. Biol. 30, 4698-4711 (2010).
195. Wu, X. et al. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol. Cell. Biol. 32, 3872-3890 (2012).
196. Wang, X. & Kim, J. Conformation-specific effects of Raf kinase inhibitors. J. Med. Chem. 55, 7332-7341 (2012).
197. V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
198. V600E mutation. Sci. Signal. 3, ra84 (2010).
199. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
200. V600E inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
201. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
202. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
203. Nussinov, R., Tsai, C. J. & Ma, B. The underappreciated role of allostery in the cellular network. Annu. Rev. Biophys. 42, 169-189 (2013).
204. Taipale, M. et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nature Biotech. 31, 630-637 (2013).
205. Girotti, M. R. et al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27, 85-96 (2015).
206. Le, K., Blomain, E. S., Rodeck, U. & Aplin, A. E. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell. Melanoma Res. 4, 509-517 (2013).
207. Holderfield, M. et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 23, 594-602 (2013).
208. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
209. Hu, J. et al. Kinase regulation by hydrophobic spine assembly in cancer. Mol. Cell. Biol. 35, 264-276 (2015).
210. Wojnowski, L., Stancato, L. F., Larner, A. C., Rapp, U. R. & Zimmer, A. Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech. Dev. 91, 97-104 (2000).
211. Wojnowski, L. et al. Craf-1 protein kinase is essential for mouse development. Mech. Dev. 76, 141-149 (1998).
212. Wojnowski, L. et al. Endothelial apoptosis in Braf-deficient mice. Nature Genet. 16, 293-297 (1997).
213. Huser, M. et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 20, 1940-1951 (2001).
214. Mikula, M. et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 20, 1952-1962 (2001).
215. Pritchard, C. A., Bolin, L., Slattery, R., Murray, R. & McMahon, M. Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr. Biol. 6, 614-617 (1996).
216. Kern, F., Doma, E., Rupp, C., Niault, T. & Baccarini, M. Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis. Oncogene 32, 2483-2492 (2013).
217. Valluet, A. et al. B-Raf and C-Raf are required for melanocyte stem cell self-maintenance. Cell Rep. 2, 774-780 (2012).
218. Giurisato, E. et al. The mitogen-activated protein kinase scaffold KSR1 is required for recruitment of extracellular signal-regulated kinase to the immunological synapse. Mol. Cell. Biol. 29, 1554-1564 (2009).
219. Kortum, R. L. et al. The molecular scaffold kinase suppressor of Ras 1 (KSR1) regulates adipogenesis. Mol. Cell. Biol. 25, 7592-7604 (2005).
220. Razidlo, G. L. et al. KSR1 is required for cell cycle reinitiation following DNA damage. J. Biol. Chem. 284, 6705-6715 (2009).
221. Costanzo-Garvey, D. L. et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell. Metab. 10, 366-378 (2009).
222. Brommage, R. et al. High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity (Silver Spring) 16, 2362-2367 (2008).
223. Pearce, L. R. et al. KSR2 mutations are associated with obesity, insulin resistance, and impaired cellular fuel oxidation. Cell 155, 765-777 (2013).
224. V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res. 65, 11493-11500 (2005).
225. Patton, E. E. et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 15, 249-254 (2005).
226. L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev. 26, 1945-1958 (2012).
227. Morrison, D. K., Kaplan, D. R., Rapp, U. & Roberts, T. M. Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity. Proc. Natl Acad. Sci. USA 85, 8855-8859 (1988).
228. Kasid, U. et al. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243, 1354-1356 (1989).
229. Morrison, D. K. et al. Direct activation of the serine/threonine kinase activity of Raf-1 through tyrosine phosphorylation by the PDGFβ-receptor. Cell 58, 649-657 (1989).
230. McGrew, B. R. et al. Phosphorylation occurs in the amino terminus of the Raf-1 protein. Oncogene 7, 33-42 (1992).
231. Leevers, S. J., Paterson, H. F. & Marshall, C. J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411-414 (1994).
232. Mott, H. R. et al. The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. Proc. Natl Acad. Sci. USA 93, 8312-8317 (1996).
233. Petosa, C. et al. 14-3-3ζ binds a phosphorylated Raf peptide and an unphosphorylated peptide via its conserved amphipathic groove. J. Biol. Chem. 273, 16305-16310 (1998).
234. Yeung, K. et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401, 173-177 (1999).
235. Lozano, J. et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer Res. 63, 4232-4238 (2003).
236. Lyons, J. F., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8, 219-225 (2001).
237. Matheny, S. A. et al. Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. Nature 427, 256-260 (2004).
238. Karasarides, M. et al. B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298 (2004).
239. Rajalingam, K. et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nature Cell Biol. 7, 837-843 (2005).
240. Lee, R. M., Cobb, M. H. & Blackshear, P. J. Evidence that extracellular signal-regulated kinases are the insulin-activated Raf-1 kinase kinases. J. Biol. Chem. 267, 1088-1092 (1992).
241. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041-3046 (2008).
242. Garcia, R., Grindlay, J., Rath, O., Fee, F. & Kolch, W. Regulation of human myoblast differentiation by PEBP4. EMBO Rep. 10, 278-284 (2009).
243. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
244. Terai, K. & Matsuda, M. The amino-terminal B-Raf-specific region mediates calcium-dependent homoand hetero-dimerization of Raf. EMBO J. 25, 3556-3564 (2006).
245. Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980-985 (2014).
246. Sarkozy, A. et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum. Mutat. 30, 695-702 (2009).
247. Kobayashi, T. et al. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum. Mutat. 31, 284-294 (2010).
248. Stokoe, D., Macdonald, S. G., Cadwallader, K., Symons, M. & Hancock, J. F. Activation of Raf as a result of recruitment to the plasma membrane. Science 264, 1463-1467 (1994).